Concepts (196)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Hemorrhagic Fever, Ebola | 6 | 2019 | 1475 | 0.96 | Why? |
| Peritoneal Cavity | 1 | 2018 | 15 | 0.77 | Why? |
| Schistosomiasis haematobia | 1 | 2018 | 45 | 0.72 | Why? |
| Myiasis | 1 | 2017 | 16 | 0.71 | Why? |
| Systems Integration | 1 | 2017 | 72 | 0.71 | Why? |
| Schistosomiasis | 1 | 2018 | 59 | 0.71 | Why? |
| Sexually Transmitted Diseases, Viral | 1 | 2018 | 115 | 0.62 | Why? |
| Malaria, Falciparum | 2 | 2018 | 377 | 0.62 | Why? |
| Ebolavirus | 4 | 2019 | 834 | 0.61 | Why? |
| Plasmodium falciparum | 1 | 2018 | 337 | 0.54 | Why? |
| Social Behavior | 1 | 2021 | 882 | 0.47 | Why? |
| Antimalarials | 4 | 2020 | 2505 | 0.46 | Why? |
| Immune Evasion | 1 | 2021 | 2081 | 0.41 | Why? |
| Robotic Surgical Procedures | 1 | 2018 | 787 | 0.41 | Why? |
| Africa, Western | 3 | 2019 | 363 | 0.37 | Why? |
| Chikungunya Fever | 3 | 2018 | 345 | 0.34 | Why? |
| Zika Virus Infection | 2 | 2018 | 1920 | 0.34 | Why? |
| Travel-Related Illness | 3 | 2019 | 1357 | 0.31 | Why? |
| Prostatic Neoplasms | 1 | 2018 | 1637 | 0.30 | Why? |
| Zika Virus | 1 | 2018 | 1924 | 0.29 | Why? |
| Molecular Diagnostic Techniques | 1 | 2018 | 4239 | 0.24 | Why? |
| Cote d'Ivoire | 2 | 2018 | 115 | 0.23 | Why? |
| Imatinib Mesylate | 2 | 2021 | 327 | 0.23 | Why? |
| Epidemics | 3 | 2017 | 6407 | 0.21 | Why? |
| France | 8 | 2020 | 12074 | 0.21 | Why? |
| Neuroschistosomiasis | 1 | 2018 | 2 | 0.20 | Why? |
| Sex Characteristics | 1 | 2007 | 1120 | 0.19 | Why? |
| Schistosoma mansoni | 1 | 2018 | 27 | 0.19 | Why? |
| Schistosoma haematobium | 1 | 2018 | 35 | 0.19 | Why? |
| Eyelids | 1 | 2018 | 40 | 0.18 | Why? |
| Mali | 1 | 2018 | 181 | 0.18 | Why? |
| Anemia, Hemolytic | 1 | 2019 | 70 | 0.18 | Why? |
| Therapies, Investigational | 1 | 2020 | 235 | 0.18 | Why? |
| Diptera | 1 | 2017 | 30 | 0.18 | Why? |
| Skin Aging | 1 | 2018 | 55 | 0.17 | Why? |
| Ebola Vaccines | 1 | 2019 | 126 | 0.17 | Why? |
| Antioxidants | 1 | 2007 | 1593 | 0.17 | Why? |
| Travel | 5 | 2020 | 7220 | 0.17 | Why? |
| Spinal Cord | 1 | 2018 | 281 | 0.17 | Why? |
| Biomedical Research | 1 | 2017 | 5270 | 0.16 | Why? |
| Arthritis, Infectious | 1 | 2018 | 111 | 0.16 | Why? |
| Hemolysis | 1 | 2019 | 283 | 0.16 | Why? |
| Artemisinins | 1 | 2018 | 238 | 0.15 | Why? |
| Histones | 1 | 2018 | 371 | 0.15 | Why? |
| Public Health | 2 | 2020 | 16359 | 0.15 | Why? |
| Dietary Supplements | 1 | 2007 | 2251 | 0.14 | Why? |
| Disease Outbreaks | 4 | 2019 | 27595 | 0.14 | Why? |
| Chikungunya virus | 1 | 2018 | 339 | 0.14 | Why? |
| Dengue | 2 | 2016 | 1565 | 0.13 | Why? |
| Skin Neoplasms | 1 | 2007 | 1679 | 0.13 | Why? |
| Prostatectomy | 1 | 2018 | 485 | 0.13 | Why? |
| Hypotension | 1 | 2016 | 392 | 0.13 | Why? |
| Pyrazines | 3 | 2020 | 1783 | 0.12 | Why? |
| Animals | 6 | 2021 | 78931 | 0.12 | Why? |
| Amides | 3 | 2020 | 1864 | 0.12 | Why? |
| Semen | 1 | 2018 | 550 | 0.12 | Why? |
| Malaria | 2 | 2019 | 1097 | 0.12 | Why? |
| Pregnancy Complications, Infectious | 1 | 2018 | 11559 | 0.12 | Why? |
| Fomites | 1 | 2017 | 709 | 0.11 | Why? |
| Viremia | 1 | 2018 | 1020 | 0.11 | Why? |
| Respiration Disorders | 1 | 2016 | 526 | 0.10 | Why? |
| Sentinel Surveillance | 1 | 2017 | 1093 | 0.10 | Why? |
| Biopsy | 1 | 2018 | 2811 | 0.10 | Why? |
| Humans | 33 | 2021 | 930598 | 0.09 | Why? |
| Prisoners | 1 | 2017 | 738 | 0.09 | Why? |
| Public Policy | 1 | 2020 | 1894 | 0.09 | Why? |
| Prisons | 1 | 2017 | 980 | 0.09 | Why? |
| Recurrence | 1 | 2018 | 3675 | 0.09 | Why? |
| Outpatients | 1 | 2020 | 3417 | 0.08 | Why? |
| Antiviral Agents | 5 | 2021 | 41703 | 0.08 | Why? |
| Guinea | 2 | 2017 | 228 | 0.08 | Why? |
| Tuberculosis, Pulmonary | 1 | 2017 | 1171 | 0.08 | Why? |
| Transients and Migrants | 1 | 2019 | 1468 | 0.08 | Why? |
| Female | 18 | 2021 | 380317 | 0.08 | Why? |
| Adult | 15 | 2021 | 244371 | 0.08 | Why? |
| Pregnancy | 2 | 2018 | 23879 | 0.07 | Why? |
| Population Surveillance | 2 | 2020 | 4967 | 0.07 | Why? |
| Middle Aged | 14 | 2020 | 270681 | 0.07 | Why? |
| International Cooperation | 1 | 2019 | 3436 | 0.07 | Why? |
| Gastrointestinal Diseases | 2 | 2019 | 2580 | 0.07 | Why? |
| World Health Organization | 1 | 2017 | 4213 | 0.07 | Why? |
| Genetic Variation | 1 | 2018 | 3919 | 0.06 | Why? |
| Male | 16 | 2021 | 367725 | 0.06 | Why? |
| Dermatology | 1 | 2017 | 1999 | 0.06 | Why? |
| RNA, Viral | 3 | 2020 | 32276 | 0.06 | Why? |
| Immunologic Factors | 1 | 2018 | 4206 | 0.06 | Why? |
| Sensitivity and Specificity | 2 | 2021 | 22971 | 0.06 | Why? |
| Luxembourg | 1 | 2020 | 125 | 0.05 | Why? |
| Drug Tolerance | 1 | 2020 | 100 | 0.05 | Why? |
| Burkina Faso | 1 | 2021 | 302 | 0.05 | Why? |
| Coercion | 1 | 2020 | 57 | 0.05 | Why? |
| Proportional Hazards Models | 2 | 2016 | 6543 | 0.05 | Why? |
| Disease Progression | 1 | 2019 | 13580 | 0.05 | Why? |
| Contact Tracing | 1 | 2020 | 8448 | 0.05 | Why? |
| Coombs Test | 1 | 2019 | 66 | 0.05 | Why? |
| Skin Diseases | 1 | 2016 | 2509 | 0.05 | Why? |
| Epithelium | 1 | 2021 | 330 | 0.05 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2018 | 11367 | 0.05 | Why? |
| Blood | 1 | 2020 | 274 | 0.05 | Why? |
| Disease Management | 1 | 2017 | 6841 | 0.05 | Why? |
| Viral Load | 4 | 2020 | 15850 | 0.04 | Why? |
| Pneumonia, Viral | 6 | 2020 | 243684 | 0.04 | Why? |
| French Guiana | 1 | 2016 | 83 | 0.04 | Why? |
| Coronavirus Infections | 6 | 2020 | 253789 | 0.04 | Why? |
| Urine | 1 | 2020 | 469 | 0.04 | Why? |
| Games, Recreational | 1 | 2016 | 18 | 0.04 | Why? |
| Hematocrit | 1 | 2016 | 107 | 0.04 | Why? |
| Rheumatic Diseases | 1 | 2013 | 2675 | 0.04 | Why? |
| SARS Virus | 1 | 2020 | 13021 | 0.04 | Why? |
| Americas | 1 | 2017 | 418 | 0.04 | Why? |
| Asia, Southeastern | 1 | 2017 | 390 | 0.04 | Why? |
| Mesocricetus | 1 | 2021 | 1847 | 0.04 | Why? |
| Administration, Intravenous | 1 | 2019 | 1115 | 0.04 | Why? |
| Africa South of the Sahara | 1 | 2019 | 1335 | 0.03 | Why? |
| Quarantine | 1 | 2020 | 18418 | 0.03 | Why? |
| Purpura | 1 | 2016 | 310 | 0.03 | Why? |
| Risk Reduction Behavior | 1 | 2020 | 946 | 0.03 | Why? |
| HIV Infections | 1 | 2019 | 11620 | 0.03 | Why? |
| Practice Guidelines as Topic | 1 | 2017 | 15421 | 0.03 | Why? |
| Chemokines | 1 | 2018 | 1095 | 0.03 | Why? |
| Risk Factors | 4 | 2019 | 71621 | 0.03 | Why? |
| Genome-Wide Association Study | 1 | 2018 | 1648 | 0.03 | Why? |
| Feasibility Studies | 1 | 2020 | 3467 | 0.03 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.03 | Why? |
| Respiratory Tract Diseases | 1 | 2019 | 1061 | 0.03 | Why? |
| Enzyme Inhibitors | 1 | 2021 | 1881 | 0.03 | Why? |
| Protein Kinase Inhibitors | 1 | 2020 | 1585 | 0.03 | Why? |
| Pandemics | 5 | 2020 | 389249 | 0.03 | Why? |
| Singapore | 1 | 2020 | 3641 | 0.03 | Why? |
| Anti-Retroviral Agents | 1 | 2019 | 1099 | 0.03 | Why? |
| Kinetics | 1 | 2018 | 3238 | 0.03 | Why? |
| Motivation | 1 | 2020 | 1640 | 0.02 | Why? |
| Europe | 2 | 2017 | 12702 | 0.02 | Why? |
| Drug Evaluation, Preclinical | 1 | 2021 | 3347 | 0.02 | Why? |
| Adolescent | 5 | 2019 | 86841 | 0.02 | Why? |
| Treatment Outcome | 3 | 2020 | 51732 | 0.02 | Why? |
| Sports | 1 | 2016 | 690 | 0.02 | Why? |
| Child, Preschool | 3 | 2017 | 36283 | 0.02 | Why? |
| Antihypertensive Agents | 1 | 2020 | 1962 | 0.02 | Why? |
| Young Adult | 5 | 2017 | 93724 | 0.02 | Why? |
| Antibodies, Viral | 2 | 2018 | 51949 | 0.02 | Why? |
| Endothelium, Vascular | 1 | 2018 | 1751 | 0.02 | Why? |
| Exanthema | 1 | 2016 | 1097 | 0.02 | Why? |
| Aged | 6 | 2021 | 215776 | 0.02 | Why? |
| Survivors | 1 | 2018 | 2619 | 0.02 | Why? |
| Feces | 1 | 2020 | 4235 | 0.02 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.02 | Why? |
| Monitoring, Physiologic | 1 | 2017 | 1956 | 0.02 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.02 | Why? |
| Cell Line | 1 | 2021 | 12040 | 0.02 | Why? |
| Ritonavir | 1 | 2020 | 4212 | 0.02 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2018 | 3607 | 0.02 | Why? |
| Referral and Consultation | 1 | 2021 | 4816 | 0.02 | Why? |
| Prevalence | 2 | 2017 | 25773 | 0.02 | Why? |
| Vero Cells | 1 | 2021 | 14117 | 0.02 | Why? |
| Aged, 80 and over | 3 | 2020 | 88759 | 0.02 | Why? |
| Age Factors | 2 | 2016 | 21039 | 0.02 | Why? |
| Seasons | 1 | 2016 | 4071 | 0.02 | Why? |
| Infant | 2 | 2016 | 30274 | 0.02 | Why? |
| Data Collection | 1 | 2013 | 1769 | 0.02 | Why? |
| Child | 3 | 2017 | 70012 | 0.02 | Why? |
| Students | 1 | 2021 | 5255 | 0.02 | Why? |
| China | 2 | 2020 | 50654 | 0.02 | Why? |
| Drug Repositioning | 1 | 2021 | 5683 | 0.01 | Why? |
| Cross-Sectional Studies | 2 | 2021 | 53120 | 0.01 | Why? |
| Fever | 1 | 2019 | 7795 | 0.01 | Why? |
| Models, Theoretical | 1 | 2020 | 6659 | 0.01 | Why? |
| Predictive Value of Tests | 1 | 2016 | 9537 | 0.01 | Why? |
| Prognosis | 2 | 2016 | 32490 | 0.01 | Why? |
| T-Lymphocytes | 1 | 2018 | 6670 | 0.01 | Why? |
| Longitudinal Studies | 1 | 2016 | 9893 | 0.01 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2021 | 13720 | 0.01 | Why? |
| Nasopharynx | 1 | 2020 | 10224 | 0.01 | Why? |
| Spain | 1 | 2019 | 15545 | 0.01 | Why? |
| Virus Replication | 1 | 2021 | 14331 | 0.01 | Why? |
| Hospitalization | 2 | 2021 | 54280 | 0.01 | Why? |
| Brazil | 1 | 2016 | 12582 | 0.01 | Why? |
| Logistic Models | 1 | 2013 | 9089 | 0.01 | Why? |
| Clinical Trials as Topic | 1 | 2017 | 7330 | 0.01 | Why? |
| Time Factors | 1 | 2020 | 31397 | 0.01 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.01 | Why? |
| Global Health | 1 | 2020 | 13911 | 0.01 | Why? |
| Cytokines | 1 | 2018 | 15010 | 0.01 | Why? |
| Prospective Studies | 1 | 2021 | 43301 | 0.01 | Why? |
| Risk Assessment | 1 | 2020 | 25439 | 0.01 | Why? |
| Inflammation | 1 | 2018 | 13255 | 0.01 | Why? |
| Biomarkers | 1 | 2018 | 23361 | 0.01 | Why? |
| Infant, Newborn | 1 | 2016 | 23105 | 0.01 | Why? |
| Incidence | 1 | 2016 | 25622 | 0.01 | Why? |
| Personal Protective Equipment | 1 | 2017 | 15978 | 0.01 | Why? |
| Lung | 1 | 2021 | 31049 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2020 | 48226 | 0.01 | Why? |
| Comorbidity | 1 | 2016 | 34796 | 0.01 | Why? |
| Cohort Studies | 1 | 2013 | 36005 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2013 | 21571 | 0.01 | Why? |
| Retrospective Studies | 1 | 2019 | 105322 | 0.01 | Why? |